轻度认知功能障碍的药物治疗研究进展

轻度认知功能障碍(mild cognitive impairment,MCI)目前已成为老年人中的一种常见疾病，是介于正常老龄与轻度痴呆之间的一种临床状态，并且以每年10%~15%的比例转变为痴呆。因此，早期对轻度认知功能障碍进行干预，改善认知功能的下降，延缓其向痴呆的转变显得尤为重要。近年来，世界范围内人们不断地通过药物、营养素的干预以及非药物治疗等方式探索更好地预防和治疗轻度认知功能障碍的方法。在药物治疗方面，主要围绕胆碱酯酶抑制剂、NMDA受体阻滞剂、麦角生物碱制剂以及脑细胞代谢复活物等几大类药物进行研究。同时在预防和控制其危险因素的药物及营养素方面也在不断地进行着有益的探索。目前还没有有力的实验证据证明和支持哪类药物对停止或逆转轻度认知功能障碍的病情有效。本文将对近年来轻度认知功能障碍的药物、营养素治疗方面的研究进行阐述，为进一步探索轻度认知功能障碍的药物治疗提供依据。 

Research progress on drug therapy of mild cognitive impairment

Mild cognitive impairment(MCI) is now a common condition in older people. It's a clinical condition between normal aging and mild dementia. Therefore, early intervention for mild cognitive impairment to improve cognitive decline and delay its transition to dementia is particularly important. In recent years, people around the world have been exploring ways to better prevent and treat MCI through drug and nutrient intervention, physical exercise, life behavior intervention and cognitive training. Whether those drugs and nutrients that can prevent and control the risk factors of mild cognitive impairment can be used in the prevention stage of MCI is worthy of attention and needs further research and confirmation. This paper will expound the research on the treatment of mild cognitive impairment drugs and nutrients in recent years, providing a basis for further exploring the drug treatment of mild cognitive impairment.